← Back to patent-cliff list
CAS 67-64-1
2-Propanal2-PropanoneAcetone
Codes: (XIV)101438-67-b, Atorvastatin-138, Molnupiravir-029
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateCardiac and vascular disordersAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHypertensionAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHeart diseaseAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin strontiumSubarachnoid haemorrhageAtorvastatin strontiumHypertensionAtorvastatin strontiumPancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelCOVID-19Molnupiravir呼吸道合胞体病毒感染MolnupiravirInfluenza virus infectionMolnupiravirRenal impairmentMolnupiravirHepatic function declineMolnupiravir
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril | Tier C — Watch / trade | - |
| Atorvastatin strontium | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Molnupiravir | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-Isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane→2-Propanal→2,2'-(Propane-2,2-diyl)bis(5,5-dimethyl-1,3,2-dioxaborinane)→5,5-Dimethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborinane→2,2'-(Propane-2,2-diyl)bis(2H-1,3,2-benzodioxaborole)→2-(Prop-1-en-2-yl)-2H-1,3,2-benzodioxaborole
Atorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilOptimised routesteps: 11total yield: 25g(Atorvastatin-017)
1,4-Epoxy-1,3-butadiene→(2E)-1,1,4,4-Tetramethoxybut-2-ene→2,2-Dimethoxyacetaldehyde→Nitrocarbol→tert-Butyl 4-bromo-3-oxobutanoate→1,1-Dimethoxy-3-nitropropan-2-ol→(1E)-3,3-Dimethoxy-1-nitroprop-1-ene→(2E)-3-Nitroprop-2-enal→Bromido(4-tert-butoxy-2,4-dioxobutyl)zinc→tert-Butyl (5S,6E)-5-hydroxy-7-nitro-3-oxohept-6-enoate→4-Methylene-2-oxetanone→tert-Butyl (3R,5S,6E)-3,5-dihydroxy-7-nitrohept-6-enoate→2-Propanone→tert-Butyl [(4R,6S)-2,2-dimethyl-6-[(E)-2-nitroethenyl]-1,3-dioxan-4-yl]acetate→(4R,6R)-6-(2-Aminoethyl)-2,2-dimethyl-1,3-Dioxane-4-acetic acid 1,1-dimethylethyl ester
Atorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilOptimised routesteps: 15total yield: 36.3gAtorvastatin-152)
(2R)-2-Aminobutanedioic acid→(2R)-2-Chlorobutanedioic acid→(2R)-2-Chlorobutane-1,4-diol→2-[(2S)-Oxiran-2-yl]ethan-1-ol→(4S,6S)-4-[2-(Benzyloxy)ethyl]-6-(bromomethyl)-1,3-dioxan-2-one→(2S)-2-[2-(Benzyloxy)ethyl]oxirane→(3R)-1-(Benzyloxy)hex-5-en-3-ol→(3R)-1-(Benzyloxy)hex-5-en-3-yl tert-butyl carbonate→(4S,6S)-4-[2-(Benzyloxy)ethyl]-6-(bromomethyl)-2,2-dimethyl-1,3-dioxane→6-O-Acetyl-1-O-benzyl-2,4-dideoxy-3,5-O-(1-methylethylidene)-D-erythro-hexitol→1-O-Benzyl-2,4-dideoxy-3,5-O-(1-methylethylidene)-D-erythro-hexitol→6-O-Benzyl-3,5-dideoxy-2,4-O-(1-methylethylidene)-L-erythro-hexose→2-[(4R,6S)-6-[2-(Benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxan-4-yl]ethanamine→(6xi)-1-O-Benzyl-2,4,7-trideoxy-3,5-O-(1-methylethylidene)-7-nitro-D-erythro-heptitol→(6xi)-6-O-Acetyl-1-O-benzyl-2,4,7-trideoxy-3,5-O-(1-methylethylidene)-7-nitro-D-erythro-heptitol→(4S,6R)-4-[2-(Benzyloxy)ethyl]-2,2-dimethyl-6-(2-nitroethyl)-1,3-dioxane→2-Propanone→Nitrocarbol→Chlorido(ethenyl)magnesium
1,4-Epoxy-1,3-butadiene→(2E)-1,1,4,4-Tetramethoxybut-2-ene→2,2-Dimethoxyacetaldehyde→Nitrocarbol→tert-Butyl 4-bromo-3-oxobutanoate→1,1-Dimethoxy-3-nitropropan-2-ol→(1E)-3,3-Dimethoxy-1-nitroprop-1-ene→(2E)-3-Nitroprop-2-enal→Bromido(4-tert-butoxy-2,4-dioxobutyl)zinc→tert-Butyl (5S,6E)-5-hydroxy-7-nitro-3-oxohept-6-enoate→4-Methylene-2-oxetanone→tert-Butyl (3R,5S,6E)-3,5-dihydroxy-7-nitrohept-6-enoate→2-Propanone→tert-Butyl [(4R,6S)-2,2-dimethyl-6-[(E)-2-nitroethenyl]-1,3-dioxan-4-yl]acetate→(4R,6R)-6-(2-Aminoethyl)-2,2-dimethyl-1,3-Dioxane-4-acetic acid 1,1-dimethylethyl ester
(2R)-2-Aminobutanedioic acid→(2R)-2-Chlorobutanedioic acid→(2R)-2-Chlorobutane-1,4-diol→2-[(2S)-Oxiran-2-yl]ethan-1-ol→(4S,6S)-4-[2-(Benzyloxy)ethyl]-6-(bromomethyl)-1,3-dioxan-2-one→(2S)-2-[2-(Benzyloxy)ethyl]oxirane→(3R)-1-(Benzyloxy)hex-5-en-3-ol→(3R)-1-(Benzyloxy)hex-5-en-3-yl tert-butyl carbonate→(4S,6S)-4-[2-(Benzyloxy)ethyl]-6-(bromomethyl)-2,2-dimethyl-1,3-dioxane→6-O-Acetyl-1-O-benzyl-2,4-dideoxy-3,5-O-(1-methylethylidene)-D-erythro-hexitol→1-O-Benzyl-2,4-dideoxy-3,5-O-(1-methylethylidene)-D-erythro-hexitol→6-O-Benzyl-3,5-dideoxy-2,4-O-(1-methylethylidene)-L-erythro-hexose→2-[(4R,6S)-6-[2-(Benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxan-4-yl]ethanamine→(6xi)-1-O-Benzyl-2,4,7-trideoxy-3,5-O-(1-methylethylidene)-7-nitro-D-erythro-heptitol→(6xi)-6-O-Acetyl-1-O-benzyl-2,4,7-trideoxy-3,5-O-(1-methylethylidene)-7-nitro-D-erythro-heptitol→(4S,6R)-4-[2-(Benzyloxy)ethyl]-2,2-dimethyl-6-(2-nitroethyl)-1,3-dioxane→2-Propanone→Nitrocarbol→Chlorido(ethenyl)magnesium
2-Isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane→2-Propanal→2,2'-(Propane-2,2-diyl)bis(5,5-dimethyl-1,3,2-dioxaborinane)→5,5-Dimethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborinane→2,2'-(Propane-2,2-diyl)bis(2H-1,3,2-benzodioxaborole)→2-(Prop-1-en-2-yl)-2H-1,3,2-benzodioxaborole
Acetone oxime→2',3'-O-(1-Methylethylidene)-5'-O-(2-methylpropanoyl)cytidine→5'-O-Isobutyryl cytidine→Acetone→2-Methylpropionic acid→Sulfuric acid 2',3'-O-(1-methylethylidene)cytidine→Isobutyric anhydride→1-(beta-D-Ribofuranosyl)cytosine→Acetone O-isobutyryloxime→N-Hydroxy-2',3'-O-(1-methylethylidene)-5'-O-(2-methylpropanoyl)cytidine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | ((3aR,4R,6R,6aR)-6-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.